The Floodlight Approach to Cardiology

For decades, genetic screening for heart disease has been a game of narrow focus. Doctors typically used monogenic tests to hunt for rare, high-impact mutations, or polygenic risk scores to calculate the cumulative effect of hundreds of tiny genetic variations. Both methods offered a glimpse into a patient’s future, but neither provided the full picture.

Now, researchers at Endeavor Health have bridged that gap. Their new diagnostic tool, the GenProb-CAD test, integrates both approaches into a single screening. By analyzing both rare mutations and broad polygenic risk—including inherited markers for Lipoprotein(a)—the test aims to illuminate the entire landscape of a patient's cardiovascular vulnerability.

Why the Timing Matters

Coronary artery disease remains the leading cause of death in the United States, claiming nearly 1 million lives in 2023. That is one death every 34 seconds. While traditional diagnostic tools like blood panels and electrocardiograms are effective at identifying existing damage, they often fail to capture risk until a patient is already symptomatic.

"Think of it like a flashlight vs. a floodlight," said Jianfeng Xu, Vice President of Translational Research at Endeavor Health and lead author of the study published in Circulation: Genomic and Precision Medicine. "The flashlight can help you see part of the picture, while a floodlight illuminates the whole landscape."

Translating Data into Clinical Practice

The study, which utilized biobank data from 450,000 individuals, demonstrated that the GenProb-CAD test identifies high-risk patients who would have been missed by traditional monogenic screening alone. Crucially, the risk levels identified by this integrated model were comparable to those found through standard clinical markers, such as high cholesterol or abnormal ECG readings.

This integration is significant because it allows clinicians to account for genetic risk alongside traditional factors like blood pressure and lipid levels. By identifying these markers early, physicians can initiate preventative strategies—such as lifestyle modifications or early pharmacological intervention—long before a cardiac event occurs.

Key Takeaways

  • Integrated Screening: The GenProb-CAD test is one of the first models to combine monogenic and polygenic risk assessment into a single, clinically available diagnostic tool.
  • Enhanced Detection: By analyzing a broader range of genetic markers, the test identifies high-risk individuals who would otherwise remain undetected by standard genetic screening.
  • Preventative Potential: The test provides an "early warning system," allowing for medical intervention before symptoms appear, rather than reactive treatment after a heart attack.

The Road Ahead for Patients

While the GenProb-CAD test is currently available exclusively within the Endeavor Health system, its implementation marks a shift in how health systems approach preventative cardiology. The program builds on Endeavor’s decade-long investment in clinical genomics, which has already screened over 80,000 patients for various genetic disorders.

For patients, the next decision point involves a conversation with their primary care physician regarding family history and eligibility. As the test is not yet covered by insurance, the barrier to entry remains cost and access. However, as more health systems move toward integrating genomic data into routine primary care, the standard for what constitutes a "comprehensive" heart health check-up is likely to evolve. Patients interested in the clinical study or testing eligibility should contact the system directly to determine if their specific risk profile warrants this advanced screening.